CLLS1045

Sigma-Aldrich

MCF10A CELLS HER2 (-/-)

eCl@ss:
32190102
NACRES:
NA.81
Pricing and availability is not currently available.

Quality Level

biological source

human female mammary glands (Source Disease: Fibrocystic Disease)

OMIM accession no.

storage temp.

−196°C

Gene Information

human ... ERBB2(2064), HER2(2064)

General description

MCF10A CELLS HER2 (-/-) are pre-neoplastic mammary epithelial cells from a human adult female with a ZFN knock out modification.
This cell line corresponds to ATCC Catalog No. CRL-10317.

Application

Cell freezing medium-DMSO 1X, Cat. No. C6164
Media renewal changes two to three times per week.
The base medium for this cell line is Dulbecco′s Modified Eagle′s Medium/Ham′s Nutrient Mixture F-12, Cat. No. 51448C. To make the complete growth medium, add the following components to the base medium: horse serum, Cat No. H1270, to a final concentration (v/v) of 5%; cholera toxin, Cat No. C8052, to a final concentration of 1 ng/mL; human insulin, Cat No. I9278, to a final concentration of 10 ug/mL; epidermal growth factor, Cat No. E9644, to a final concentration of 10 ng/mL; and hydrocortisone, Cat No. H6909, to a final concentration of 0.5 ug/mL.
Rapidly thaw vial by gentle agitation in 37°C water bath (~2 minutes), keeping vial cap out of the water. Decontaminate with 70% ethanol, add 9 mL culture media and centrifuge 125 x g (5-7 minutes). Resuspend in complete culture media and incubate at 37°

Biochem/physiol Actions

Human epidermal growth factor receptor 2 (HER2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, overexpression of this protein causes breast cancer. Heterodimeric complex of HER2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of HER2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of HER2. This domain is missing in p95, a truncated form of HER2, and hence these cancer cells show resistance to trastuzumab. HER2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.

Features and Benefits

Zinc finger nuclease (ZFN) knockout on chromosome 17q21.1
These MCF10A cells are adherent with a doubling time of approx. 20 hours

Quality

Tested for Mycoplasma, sterility, post-freeze viability, short terminal repeat (STR) analysis for cell line identification, cytochrome oxidase I (COI) analysis for cell line species confirmation.

Kit Components Also Available Separately

Product No.
Description
SDS

  • MCF10A CONTROL CELLS 1 vial

  • MCF10A CELLS HER2 (-/-) 1 vial

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
HER2: biology, detection, and clinical implications.
Gutierrez C and Schiff R.
Archives of Pathology & Laboratory Medicine, 135(1), 55-62 (2011)
The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21(2), 382-389 (2016)
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP, et al.
Molecular Diagnosis & Therapy, 17(2), 85-99 (2013)
Related Content
We have applied our revolutionary CompoZr Zinc Finger Nuclease technology to create an unparalleled range of genetically modified mammalian cell lines for use in areas, such as target validation, drug discovery and drug development.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.